CD19 and cancer: In a clinical trial, cells expanded between days 3 and 14 and could be detected for at least 12 months in the patients’ blood (NCT03056339, phase 1/2 trial of HLA-mismatched anti-CD19 UCB-CAR-NK in 11 patients with relapsed or refractory CD19-positive cancers) [62].